Stocks Under $5 Least Likely to Go Bankrupt

BOSTON (TheStreet) -- Companies that trade for less than $5 a share typically are viewed as speculative and at risk of going broke. That's not always the case. Fortunately for investors, there is a reliable measure to help predict a company's bankruptcy risk.

The Altman Z-score, a formula developed by New York University professor Edward Altman in 1968, measures companies' financial health to predict which may enter bankruptcy within two years. The gauge was 80% to 90% accurate on samples of distressed firms one year prior to bankruptcy by examining working capital, retained earnings and other measures, according to Altman's study.

Altman Z-scores carry three classifications. Companies with an Altman Z-score of at least 3 are considered "safe," while those with 1.8 or less are "distressed." Those in between are in a gray zone. Some stocks trading under $5 even have a negative score.

TheStreet ranked companies on the New York Stock Exchange, NYSE Amex and Nasdaq trading at less than $5 with a minimum $5 million market value and the highest Altman Z-score. Each company's quick ratio is given, helping to measure the ability to meet short-term obligations.


5. American DG Energy ( ADGE)

Company Profile: American DG Energy distributes, owns and operates clean, on-site energy systems that produce electricity, hot water, heat and cooling.

Altman Z-score: 54.8

Closing Price: $3.15 (Sept. 15)

Financial Metrics: American DG Energy has a price-to-book ratio of 11.8, which suggests the stock may be overvalued based on book value. American DG Energy's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is 1.4, indicating the energy-systems company should be able to meet its current liabilities.

Analyst Consensus: There are currently no research firms with coverage of American DG Energy.

4. BioTime ( BTIM)

Company Profile: BioTime is engaged in the business of developing blood plasma volume expanders and related products and stem-cell-related products, and technology for diagnostic, therapeutic and research use.

Altman Z-score: 55.66

Closing Price: $4.65 (Sept. 15)

Financial Metrics: BioTime has a price-to-book ratio of 7.22, which suggests the stock may be overvalued based on book value. BioTime's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is a whopping 13, indicating the company would have no trouble meeting its current liabilities.

Analyst Consensus: No analyst has coverage on BioTime.

3. Uranerz Energy ( URZ)

Company Profile: Uranerz Energy is an exploration-stage company engaged in the acquisition, exploration and development of properties in the uranium industry.

Altman Z-score: 66.26

Closing Price: $1.31 (Sept. 15)

Financial Metrics: Uranerz Energy has a price-to-book ratio of 3.33, which suggests the stock may be slightly overvalued based on book value. Uranerz's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is 27, a sign the uranium company should easily be able to meet its current liabilities.

Analyst Consensus: Two analysts cover Uranerz Energy and both recommend that investors buy shares. That's down from three "buy" ratings a month ago.

2. Rexahn Pharmaceuticals ( RNN)

Company Profile: Rexahn Pharmaceuticals is a clinical-stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system to patients worldwide.

Altman Z-score: 69

Closing Price: $1.24 (Sept. 15)

Financial Metrics: Rexahn Pharmaceuticals has a price-to-book ratio of 6.25, which suggests the stock may be overvalued based on book value. Rexahn's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is 11, indicating the biopharmaceutical company would be able to meet its current liabilities.

Analyst Consensus: No research firm has coverage on Rexahn, although one had a "buy" rating on the stock about three months ago.

1. Pure Bioscience ( PURE)

Company Profile: Pure Bioscience develops bioscience products, including antimicrobials.

Altman Z-score: 69.8

Closing Price: $2.05 (Sept. 15)

Financial Metrics: Pure Bioscience has a price-to-book ratio of 11.9, which suggests the stock may be overvalued based on book value. Pure's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is 4.9, indicating the company should be able to meet its current liabilities.

Analyst Consensus: Only one firm follows Pure Bioscience, recommending that investors buy shares of the bioscience products maker

-- Written by Robert Holmes in Boston.

>To contact the writer of this article, click here: Robert Holmes.

>To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet.

>To submit a news tip, send an email to: tips@thestreet.com.

READERS ALSO LIKE:



Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

More from Personal Finance

When Is the FAFSA Deadline and What Are the Application Requirements?

When Is the FAFSA Deadline and What Are the Application Requirements?

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

Former General Electric CEO Jack Welch Has 4 Tips to Getting a Promotion

Former General Electric CEO Jack Welch Has 4 Tips to Getting a Promotion

What Is Neymar's Net Worth?

What Is Neymar's Net Worth?

How to Make a Fortune Like Microsoft Billionaire Founder Bill Gates

How to Make a Fortune Like Microsoft Billionaire Founder Bill Gates